News

Tue, 22/10/2019
The key lies in cell metabolism: Neuroscientist and neurologist Luisa Klotz wins renowned Heinrich-Pette-Award
Münster. For the third time the renowned neuroscience award “Heinrich Pette prize” goes to Münster, as this year Luisa Klotz was rewarded with the prestigious award for neuroscience researchers and clinicians at the congress of the German Society of Neurology in Stuttgart. Neurologist and Neuroscientist Luisa Klotz received the award for her outstanding research in […]...more
Mon, 07/10/2019
Talk “Der Einfluss der Ernährung und des Darms auf die Multiple Sklerose”
Muenster. The department of neurology with Institute of Translational Neurology warmly welcomes SFB 128-PI Prof. Aiden Haghikia, leading senior physician at the Department of Neurology at Bochum University Clinic. His talk “Der Einfluss der Ernährung und des Darms auf die Multiple Sklerose” provides insights into his latest research progress in this field. Time: Wednesday, October […]...more
Mon, 03/06/2019
Publication: Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Muenster. For the first time scientists from the University of Münster could show that multiple sclerosis (MS) alters the energy metabolism of T cells during acute phases of disease exacerbation. Therapeutic interventions targeting the metabolism of activated T cells display new potential avenues for treatment of patients with MS affecting around 250,000 people in Germany. The […]...more


Mon, 03/06/2019 | Publication: Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.

Muenster. For the first time scientists from the University of Münster could show that multiple sclerosis (MS) alters the energy metabolism of T cells during acute phases of disease exacerbation. Therapeutic interventions targeting the metabolism of activated T cells display new potential avenues for treatment of patients with MS affecting around 250,000 people in Germany. The results of the study have recently been published in the renowned journal Science Translational Medicine. In a clinical trial, the authors investigated the effects of the MS drug teriflunomide in patients and analyzed its effects on immune cells. They could reveal that the drug specifically interferes with the energy metabolism of T cells and thereby preferentially affects highly active immune cells. “The drug specifically interferes with the activation of these cells already in the early initiation phase”, explains Luisa Klotz, first author of the article and principal investigator at the DFG-funded collaborative research centre 128 “Multiple Sclerosis”. Science Translational Medicine doi: 10.1126/ scitranslmed. aao5563.